食管癌免疫治疗研究进展

doi:10.11904/j.issn.1002-3070.2021.01.008

摘要/Abstract

摘要： 食管癌(Esophageal cancer,EC)是一种具有高度侵袭性且预后较差的恶性肿瘤,2018年全球食管癌发病率居第7位,死亡率居第6位。中国食管癌新发病例占全球新发病例的54.1%,死亡病例占全球死亡病例的56%。目前,食管癌的标准治疗方案包括手术、放疗和化疗,尽管使用了多学科疗法,食管癌患者的预后仍不理想,5年总生存率仅为30%~40%。免疫治疗作为新兴治疗手段,为多种恶性肿瘤提供了新的治疗思路,大大改善了恶性黑色素瘤、非小细胞肺癌等肿瘤患者的预后。许多Ⅱ、Ⅲ期临床试验证实免疫治疗联合放化疗可以增强抗肿瘤作用。本文就目前免疫治疗在食管癌中的临床研究展开论述。

关键词: 食管癌, 免疫治疗, 帕博利珠单抗, 纳武单抗, 伊匹单抗

Abstract: Esophageal cancer(EC)is a highly aggressive malignant tumor with a poor prognosis.In 2018,the incidence of EC is ranked the seventh in the world,and the sixth in the mortality.New cases of EC in China account for 54.1% of new cases worldwide,and deaths account for 56% of global deaths.Currently,standard treatment options for EC include surgery,radiotherapy,and chemotherapy.Despite the use of multidisciplinary therapies,the prognosis of EC patients is still unsatisfactory.The 5-year overall survival rate is only 30% to 40%.Immunotherapy,as a new treatment method,provides new treatment ideas for a variety of malignant tumors,and has greatly improved the prognosis of patients with malignant melanoma,non-small cell lung cancer and other tumor patients.Many phase Ⅱ/Ⅲ clinical trials have confirmed that immunotherapy combined with radiochemotherapy can enhance the anti-tumor effect.This article discusses the current clinical research of immunotherapy in EC.

Key words: Esophageal cancer, Immunity therapy, Pabolizumab, Nivolumab, Ipilimumab

中图分类号:

R735.1

李瑞阳,方琳(综述),张艳桥(审校). 食管癌免疫治疗研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 41-45.

LI Ruiyang,FANG Lin,ZHANG Yanqiao. Research progress on immunotherapy of esophageal cancer[J]. Journal of Practical Oncology, 2021, 35(1): 41-45.

参考文献

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 杜灵彬,魏文强.中国人群食管鳞癌生存分析研究新进展[J].实用肿瘤学杂志,2018,32(4):344-348.
3 Ferlay J,Soerjomataram I,Dikshit R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,13(6):359-386.
4 Karlsson AK,Saleh SN.Checkpoint inhibitors for malignant melanoma:A systematic review and meta-analysis[J].Clin Cosmet Investig Dermatol,2017,24(10):325-339.
5 Herzberg B,Campo MJ,Gainor JF.Immune checkpoint inhibitors in non-small cell lung cancer[J].Oncologist,2017,22(1):81-88.
6 Weichselbaum RR,Liang H.Radiotherapy and immunotherapy:A beneficial liaison?[J].Nat Rev Clin Oncol,2017,14(6):365-379.
7 Aoto K,Mimura K,Okayama H,et al.Immunogenic tumor cell death induced by chemotherapy in patients with breast cancer and esophageal squamous cell carcinoma[J].Oncol Rep,2018,39(1):151-159.
8 Kroemer G,Galluzzi L,Kepp O.Immunogenic cell death in radiation therapy[J].Annu Rev Immunol,2013,2(10):51-72.
9 Hong MH,Kim HR,Park SY,et al.A phase Ⅱ trail of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma(ESCC)[J].J Clin Oncol,2019,37(15):4027.
10 Hirva M,Bryan JS,Laith IA,et al.Safety and efficacy of durvalumab following multimodality therapy for locally advanced esophageal and GEJ adenocarcinoma:results from big ten cancer research consortium study[J].J Clin Oncol,2019,37(15):e16070.
11 Kitagawa Y,Doki Y,Kato K,et al.Two year survival and safety update for esophageal squamous cell carcinoma treated with nivolumab[J].Ann Oncol,2017,28(5):209-268.
12 Yuriy Y,Alexander PO,Calvo E,et al.Nivolumab ± ipilimumab in pts with advanced(adv)/metastatic chemotherapy-refractory(CTx-R)gastric(G),esophageal(E),or gastroesophageal junction(GEJ)cancer:CheckMate 032 study[J].J Clin Oncol,2017,35(15):4014.
13 Greally M,Molena D,Sihag S,et al.Phase Ib/II trial of durvalumab and chemoradiation(CRT)with carboplatin/paclitaxel for esophageal and gastroesophageal junction(GEJ)adenocarcinoma[J].J Clin Oncol,2018,36(4):172.
14 Chung HC,Arkenau HT,Wyrwicz L,et al.Safety,PD-L1 expression,and clinical activity of avelumab(MSB0010718C),an anti-PD-L1 antibody,in patients with advanced gastric or gastroesophageal junction cancer[J].J Clin Oncol,2016,34(4):167.
15 Smyth E,Thuss-Patience PC.Immune checkpoint inhibition in gastro-oesophageal cancer[J].Oncol Res Treat,2018,41(5):272-280.
16 Bang Y,Golan T,Lin CC,et al.Interim safety and clinical activity in patients(pts)with locally advanced and unresectable or metastatic gastric or gastroesophageal junction(G/GEJ)adenocarcinoma from a multicohort phase I study of ramucirumab(R)plus durvalumab(D)[J].J Clin Oncol,2018,36(4):92.
17 Vrána D,Matzenauer M,Melichar B.Current status of checkpoint inhibitors in the treatment of esophageal and gastric tumors-verview of studies[J].Klin Onkol,2017,31(1):35-39.
18 Doi T,Piha-Paul SA,Jalal SI,et al.Pembrolizumab(MK-3475)for patients(pts)with advanced esophageal carcinoma:preliminary results from KEYNOTE-028[J].J Clin Oncol,2015,33(15):4010.
19 Doi T,Bennouna J,Shen L,et al.NOTE-181:phase 3,open-label study of second-line pembrolizumab vs single-agent chemotherapy in patients with advanced/metastatic esophageal adenocarcinoma[J].J Clin Oncol,2017,37(4):2.
20 Kato K,Satoh T,Muro K,et al.A subanalysis of Japanese patients in a randomized,double-blind,placebo-controlled,phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to,or intolerant of,at least two previous chemotherapy regimens(ONO-4538-12,ATTRACTION-2)[J].Gastric Cancer,2019,22(2):344-354.
21 Li W,Wei Z,Yang X,et al.Salvage therapy of reactive capillary hemangiomas:apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer[J].Cancer Res Ther,2019,15(7):1624-1628.
22 Teng Y,Guo RF,Sun JF,et al.Reactive capillary hemangiomas induced by camrelizumab(SHR-1210),an anti-PD-1 agent[J].Acta Oncol,2019,58(3):388-389.
23 Shah MA,Kojima T,Enzinger PC,et al.Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus:phase 2 keynote-180 study[J].J Clin Oncol,2018,36(15):4049.
24 Tabernero J,Cutsem EV,Bang Y,et al.Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction(G/GEJ)adenocarcinoma:The Phase 3 KEYNOTE-062 Study[J].Ann Oncol,2019,30(4):152-153.
25 Ajani JA,D'Amico TA,Bentrem DJ,et al.Esophageal and esophagogastric junction cancers,version 2.2019,NCCN clinical practice guidelines in oncology[J].J Natl Compr Canc Netw,2019,17(7):855-883.
26 Liang F.The KEYNOTE-061 trial[J].Lancet,2019,393(10176):1098.
27 Fuchs CS,Doi T.Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer:phase 2 clinical KEYNOTE-059 trial[J].JAMA Oncology,2018,4(5):e180013.

[1]	刘学静(综述),徐燕颖(审校). B7-H6在恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 46-49.
[2]	张璐,陆静钰(综述),陆海军(审校). 头颈部鳞癌相关生物标志物与免疫治疗预后的关系[J]. 实用肿瘤学杂志, 2021, 35(1): 55-58.
[3]	范晓娜, 王丹, 黎清炜, 李志伟. 胰腺癌术后辅助药物治疗的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 249-253.
[4]	侯建英, 朱巍. 免疫抑制剂PD-1/PD-L1治疗卵巢癌的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 266-270.
[5]	刘超, 郑桐森. 新冠肺炎时期肿瘤内科工作的总结和反思[J]. 实用肿瘤学杂志, 2020, 34(2): 100-102.
[6]	赵楠楠, 秦文, 韩永焕, 鲁静, 李亚敏, 徐亚君. SOX11 抑制食管癌细胞增殖和迁移的机制研究[J]. 实用肿瘤学杂志, 2020, 34(1): 17-23.
[7]	曹涤非, 黄国庆, 薛佳莹, 吴琼, 王雷, 李瑶. CA153在乳腺癌免疫治疗中的作用[J]. 实用肿瘤学杂志, 2019, 33(6): 566-569.
[8]	姚洋张艳桥. 胃癌免疫检查点抑制剂作用机制及最新研究进展[J]. 实用肿瘤学杂志, 2019, 33(4): 371-375.
[9]	刘仲阳, 袁欣, 周文, 李晓亮, 樊立茂. 微创小切口手术对早期胸中下段食管癌患者的治疗效果及对其疼痛的影响[J]. 实用肿瘤学杂志, 2019, 33(1): 57-61.
[10]	于芳, 赵培. TRAP1在食管癌发展中的作用及机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 515-519.
[11]	杜灵彬, 魏文强. 中国人群食管鳞癌生存分析研究新进展[J]. 实用肿瘤学杂志, 2018, 32(4): 344-348.
[12]	孙祖刚, 王哲, 陈怀安, 刘硕, 苗文隆. 诱发膀胱癌的常见慢性炎症因素及其免疫治疗的研究进展[J]. 实用肿瘤学杂志, 2018, 32(4): 357-361.
[13]	张婷, 贾迪(综述), 杨丹(审校). 骨肉瘤的生物学治疗进展[J]. 实用肿瘤学杂志, 2018, 32(3): 254-257.
[14]	苗素平, 郭二亮, 裴荣, 姜寰宇, 苗素生. miRNA调节免疫检查点在肿瘤治疗中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 57-62.
[15]	曾玉兰,刘洋洋,梁金燕,谷飞飞,刘莉. 免疫检查点抑制剂耐药机制及耐药后治疗策略的研究进展[J]. 实用肿瘤学杂志, 2017, 31(4): 353-358.